Brown and beige fat are specialized adipose tissues found in almost all mammals that can increase energy expenditure and produce heat. Cold exposure and b3-adrenergic stimulation has been extensively shown to activate brown adipose tissue (BAT) in rodents, which promotes uncoupled respiration of glucose and lipid substrates via uncoupling protein 1 (UCP1). Prolonged stimulation can induce white adipose browning, which leads to the emergence of thermogenic cells within white fat depots, called beige adipocytes. The beige adipocyte possesses a unique molecular signature, yet shares several characteristics of brown adipocytes, including high mitochondrial content. When activated, beige fat can be induced to initiate a thermogenic transcriptional program similar to that of BAT. Recent human studies have identified brown and/or beige fat in the supraclavicular region using various radiation imaging modalities. This remarkable discovery has reinvigorated scientific interest in adipose browning and brown/beige fat activation as possible therapeutic targets for obesity. Like in rodents, several groups have previously tested the potential impact of cold exposure and b3-adrenergic agonism on BAT-mediated thermogenesis in humans. However, even though these approaches were shown to significantly increase energy expenditure and promote weight loss in obese individuals, they are not ideal clinical interventions. Cold exposure is uncomfortable and requires prolonged treatment, while b3-adrenergic agonists may lead to many adverse effects like cardiovascular problems. This thesis will evaluate the therapeutic potential and clinical relevance of alternative anti-obesity approaches that target adipose browning and beige adipose activation.

Obesity is a disorder of energy imbalance in which energy intake exceeds energy expenditure (EEX). Brown adipose tissue (BAT) is unique in that it can increase whole body EEX when it is adrenergically activated. The thermogenic capacity of BAT is mediated by mitochondrial uncoupling through the activation of Uncoupling Protein 1 which uncouple respiration from ATP production. Mitochondria is a dynamic organelle that undergo continuous cycles of fusion and fission. Alteration in mitochondrial dynamics correlates with changes in energy efficiency in different cell types; however, its role in regulating EEX in BAT has not been investigated. Here we describe that mitochondrial dynamics is a physiological regulator of adrenergically-induced changes in EEX in BAT. Norepinephrine (NE) induces mitochondrial fragmentation in brown adipocytes (BA) though posttranslational modifications - phosphorylation and proteolytic cleavage -of mitochondrial dynamic proteins. NE-induced EEX is reduced in fission-deficient brown adipocytes while forced mitochondrial fragmentation increases the respiration in response to exogenous free fatty acids (FFAs) indicating increase in EEX. We further investigated whether forced mitochondrial fragmentation in BAT could be utilized as an approach to increase whole body EEX is response to FFA in vivo. We found that a mouse model with forced mitochondrial fragmentation in BAT (BAT-Mitofusin2-KO) gained less body weight and less fat mass and remained more glucose tolerant and insulin sensitive under high fat diet (HFD) compared to the wild type. Additionally, FFA oxidation was enhanced in BAT-Mitofusin2-KO mice indicated by lower respiratory exchange ratio. We also found that subcellular heterogeneity in dynamics leads to the generation of subpopulations of mitochondria with diverse bioenergetics characteristics within the same cell. We described that a subpopulation of mitochondria surrounding the lipid droplet in BA had higher ATP synthesis capacity, supported by higher ATP synthase protein expression and elongated morphology. We suggest that this subpopulation of mitochondria is responsible for addressing the ATP demand of the BA when it is not activated. In conclusion, changes to mitochondrial dynamics are required for BAT thermogenic activity and for the control of EEX efficiency from sub-cellular to the whole body level. Additionally, mitochondrial dynamics in BAT can regulate fatty acid oxidation. / 2018-06-15T00:00:00Z

Due to the high childhood obesity rates within the United States, it is necessary to develop efficacious strategies to combat childhood obesity. To explore whether early intervention can produce lasting metabolic improvements, we used a mouse model of genetically-induced hypothalamic leptin resistance (LeprNkx2.1knockout, hereby known as KO) that exhibits early-onset hyperphagia and obesity. We found that KO mice exhibit reduced capacity of the brown adipose tissue (as seen by disorganized mitochondrial structure). Brown adipose tissue capacity can be restored by paired-feeding in the peri-weaning period, leading to persistent improvements in later adiposity even after restriction ends. These studies lead us to investigate the maturation process of brown adipose tissue in the peri-weaning period. We found that brown adipose tissue expansion between 2 to 3 weeks of age is accompanied by a reduced thermogenic capacity in control mice, as determined by protein levels of uncoupling protein 1 and disorganization of the mitochondrial cristae. Thermogenic function was restored by 5 weeks of age, as demonstrated by a peak of uncoupling protein 1, in control mice but not KO mice. Paired-feeding of KO mice in the peri-weaning period rescued this peak at 5 weeks of age. These studies elucidate a critical period when brown adipose tissue expansion is followed by activation. The magnitude of brown adipose tissue activation at this time might be predictive of future obesity and metabolic rate, highlighting a potential therapeutic time window in which to intervene in pediatric obesity.

Conselho Nacional de Desenvolvimento Científico e Tecnológico / A obesidade é um dos maiores problemas de saúde pública que cresce em todo o mundo, resultante de um desequilíbrio entre ingestão alimentar e gasto energético. O aumento da adiposidade leva ao desenvolvimento de alterações funcionais. Pode-se dizer que a obesidade é o principal fator de risco para o desenvolvimento de doenças crônicas de maior prevalência como dislipidemias, doenças cardiovasculares e diabetes do tipo 2, acarretando na redução da qualidade e expectativa de vida. A Grelina é um hormônio sintetizado pelo estômago, que atua em diferentes tecidos através de um receptor específico (GHS-R1a), incluindo hipotálamo e tecido adiposo. A grelina tem uma ação direta sobre a regulação hipotalâmica da ingestão alimentar, induzindo um efeito orexígeno. Por outro lado, a grelina também modula o armazenamento de energia nos adipócitos. Esta dupla ação sugere que este hormônio pode atuar como uma ligação entre o sistema nervoso central e mecanismos periféricos. Portanto, considerando que a hiperalimentação neonatal induz obesidade na idade adulta por mecanismos desconhecidos, neste estudo foram pesquisados os efeitos da hiperalimentação no início da vida sobre o desenvolvimento da obesidade e, em particular, a sinalização da grelina no tecido adiposo em ratos jovens e adultos. Foram utilizados camundongos Swiss hiperalimentados através do modelo de redução da ninhada. Para induzir a hiperalimentação as ninhadas foram reduzidas a 3 filhotes machos por lactante no 30 dia de vida pós-natal. As ninhadas controles foram ajustadas em 9 filhotes por lactante. Foram avaliados parâmetros antropométricos como: massa corporal e massa do tecido adiposo visceral. A glicemia de jejum foi avaliada utilizando glicosímetro e fitas teste. A análise do conteúdo das proteínas envolvidas na via de sinalização da grelina foram detectadas pelo método de Western Blotting. Os grupos controle (C) e hiperalimentado (H) foram estudados aos 21 e 180 dias de vida. Os dados demonstram que a hipernutrição no início da vida induz um aumento significativo no peso corporal dos camundongos jovens, começando aos 10 dias, e este aumento de peso persistiu até à idade adulta (180 dias de idade). A glicemia e o peso da gordura visceral foram significativamente maiores no grupo hiperalimentado aos 21 e 180 dias, quando comparado com o grupo controle. Os níveis plasmáticos de grelina acilada apresentaram uma redução de 70% nos animais jovens e 49% adultos obesos. Além disso, no tecido adiposo branco, observamos um maior conteúdo (242%) do receptor de grelina (GHSR1a) nos animais hiperalimentados com 21 dias, e este aumento foi associado à modulação positiva do conteúdo e fosforilação de proteínas envolvidas no estoque e utilização de energia celular, tais como AKT, PI3K, AMPK, GLUT-4, e CPT1. No entanto, ao chegar à idade adulta os animais hiperalimentados não apresentaram diferença significativa no conteúdo de GHS-R1a e das proteínas AKT, PI3K, AMPK, GLUT-4, e CPT1. O conteúdo de PPARɣ foi menor no grupo obeso aos 21e 180 dias. Basicamente, mostramos que o metabolismo do tecido adiposo está alterado na obesidade adquirida no início da vida e, provavelmente, devido a essa modificação, ocorre um novo padrão da via de sinalização da grelina. / Obesity is a major public health problem that is growing worldwide, due to an imbalance between food intake and energy expenditure is a major risk factor for the development of most prevalent chronic diseases as dyslipidemias, heart disease and type 2 diabetes, resulting in reduced quality and life expectancy. Ghrelin is a hormone synthesized by the stomach that acts in different tissues via a specific receptor (GHS-R1a), including hypothalamus and adipose tissue. For instance, recent reports have shown that ghrelin has a direct action on hypothalamic regulation of food intake mainly inducing an orexigenic effect. On the other hand, ghrelin also modulates energy stores and expenditure in the adipocytes. This dual action has suggested that this hormone may act as a link between the central nervous system and peripheral mechanisms. Furthermore, concerning nutritional disorders, it has been suggested that obesity may be considered an impairment of the above cited link. Therefore, considering that neonatal overfeeding induces obesity in adulthood by unknown mechanisms, in this study we examined the effects of early life overnutrition on the development of obesity and in particular on adipose tissue ghrelin signaling in young mice. Our data demonstrated that overnutrition during early life induces a significant increase in body weight of young mice, starting at 10 days, and this increase in weight persisted until adulthood (180 days of age). In these animals, blood glucose and visceral fat weight were found higher at 21 and 180 days when compared to the control group. Acylated ghrelin circulating levels were found lower in the young obese pups and adult obese mice. In addition, in white adipose tissue ghrelin receptor (GHS-R1a) expression increased and was associated to positive modulation of content and phosphorylation of proteins involved in cell energy store and use as AKT, PI3K, AMPK, GLUT-4, and CPT1. However adulthood overfeeding animals showed no significant difference in the content of GHS-R1a and protein AKT, PI3K, AMPK, GLUT-4, and CPT1. PPARγ content decreased in obese group at 21 and 180 days. Basically, we showed that adipose tissue metabolism is altered in early life acquired obesity and probably due to such modification a new pattern of ghrelin signaling pathway takes place.

Wu, Hoi Yan. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 92-104). / Abstracts in English and Chinese. / Thesis/ Assessment Committee --- p.i / Declaration --- p.ii / Acknowledgments --- p.vi / Table of Content --- p.vii / List of Abbreviations --- p.x / List of Figures --- p.xiv / List of Tables --- p.xv / Chapter 1. --- Literature Review --- p.1 / Chapter 1.1 --- Introduction of diabetes mellitus --- p.1 / Chapter 1.1.1 --- Definition and prevalence --- p.1 / Chapter 1.1.2 --- Diagnosis and classification --- p.2 / Chapter 1.1.3 --- Symptoms and complications --- p.4 / Chapter 1.1.4 --- Cause and risk factors --- p.5 / Chapter 1.1.5 --- Prevention and treatment --- p.9 / Chapter 1.2 --- The role of adipose tissue in pathophysiology of T2DM --- p.10 / Chapter 1.2.1 --- Randle's glucose-fatty acid hypothesis --- p.11 / Chapter 1.2.2 --- Ectopic fat storage hypothesis --- p.12 / Chapter 1.2.3 --- Adipose tissue as an endocrine organ --- p.13 / Chapter 1.2.4 --- Low-grade inflammation --- p.15 / Chapter 1.2.5 --- Endoplasmic reticulum (ER) stress --- p.17 / Chapter 1.3 --- Use of berberine in the treatment of T2DM --- p.18 / Chapter 1.3.1 --- Efficacy of berberine in treating diabetes --- p.18 / Chapter 1.3.2 --- Berberine on glucose and lipid metabolism of animals --- p.19 / Chapter 1.3.3 --- Inhibition of adipogenesis --- p.20 / Chapter 1.3.4 --- Activation of AMP-Activated Protein Kinase (AMPK) --- p.20 / Chapter 1.3.5 --- Mitochondrial inhibition --- p.21 / Chapter 1.4 --- Introduction of proteomics --- p.21 / Chapter 1.4.1 --- Why proteomics? --- p.22 / Chapter 1.4.2 --- Gel-based proteomics: Two-Dimensional Gel Electrophoresis --- p.23 / Chapter 1.4.3 --- Gel-free proteomics --- p.25 / Chapter 1.4.4 --- Mass spectrometry --- p.26 / Chapter 1.4.5 --- Proteomics as tool for diabetes research --- p.27 / Chapter 1.5 --- Objectives and significance --- p.32 / Chapter 2. --- Materials and Methods --- p.34 / Chapter 2.1 --- Drug preparation --- p.34 / Chapter 2.2 --- Animal experiment --- p.34 / Chapter 2.3 --- Comparison of proteome of visceral white adipose tissue: obese db/db micevs lean m+/db mice and BBR-treated vs control db/db mice --- p.36 / Chapter 2.3.1 --- Protein sample preparation from adipose tissue --- p.36 / Chapter 2.3.2 --- Protein quantitation --- p.37 / Chapter 2.3.3 --- 2D Gel electrophoresis --- p.37 / Chapter 2.3.4 --- Image analysis --- p.39 / Chapter 2.3.5 --- In-gel digestion and MALDI-ToF MS --- p.39 / Chapter 2.4 --- Cell culture experiment --- p.40 / Chapter 2.5 --- Oil Red O staining --- p.42 / Chapter 2.6 --- Glycerol determination --- p.42 / Chapter 2.7 --- Comparison of proteomes of BBR-treated and control 3T3-L1 adipocytes..… --- p.43 / Chapter 2.7.1 --- Protein sample preparation from 3T3-L1 cells --- p.43 / Chapter 2.7.2 --- Protein quantitation --- p.43 / Chapter 2.7.3 --- 2D Gel electrophoresis --- p.44 / Chapter 2.7.4 --- Image analysis --- p.44 / Chapter 2.7.5 --- In-gel digestion and MALDI-ToF MS --- p.44 / Chapter 2.8 --- Western Immunoblotting --- p.44 / Chapter 2.8.1 --- Protein sample preparation of BBR-treated and control 3T3-L1 --- p.44 / Chapter 2.8.2 --- SDS-PAGE --- p.44 / Chapter 2.8.3 --- Protein blotting --- p.45 / Chapter 2.8.4 --- Membrane blocking and antibody incubations --- p.45 / Chapter 2.8.5 --- Detection of Proteins --- p.46 / Chapter 2.9 --- Statistical analysis --- p.46 / Chapter 3. --- Results --- p.47 / Chapter 3.1 --- Comparison of total protein profiles of visceral adipose tissue of obese db/db and lean m+/db mice --- p.47 / Chapter 3.2 --- Effect of berberine on glucose metabolism of obese db/db mice --- p.53 / Chapter 3.3 --- Comparison of the protein profiles of visceral adipose tissue of BBR-treated and control db/db mice --- p.55 / Chapter 3.4 --- Effect of berberine treatment on 3T3-L1 adipocytes --- p.61 / Chapter 3.4.1 --- Berberine treatment inhibited intracellular triglyceride accumulation in both mature and pre-mature 3T3-L1 adipocytes --- p.61 / Chapter 3.4.2 --- Berberine treatment enhanced lipolysis in mature 3T3-L1 adipocytes but inhibited lipolysis in pre-mature 3T3-L1 adipocytes --- p.65 / Chapter 3.4.3 --- Color change in culture media after berberine treatment --- p.65 / Chapter 3.4.4. --- Comparison of protein profiles between berberine-treated and control 3T3-L1 adipocytes --- p.67 / Chapter 3.4.5 --- Western blotting --- p.73 / Chapter 4. --- Discussion --- p.75 / Chapter 4.1 --- Comparison of total protein profiles of visceral adipose tissue of obese db/db and lean m+/db mice --- p.75 / Chapter 4.2 --- "Berberine lowers body weight, reduces fasting blood glucose level and improves glucose-lowering ability of db/db mice" --- p.78 / Chapter 4.3 --- Comparison of the protein profiles of visceral adipose tissue of BBR-treated and control db/db mice --- p.79 / Chapter 4.4 --- Berberine inhibited lipid accumulation in mature and pre-mature 3T3-L1 adipocytes --- p.84 / Chapter 4.5 --- Berberine enhanced lipolysis in mature 3T3-L1 adipocytes but inhibited lipolysis in pre-mature 3T3-L1 adipocytes --- p.84 / Chapter 4.6 --- Comparison of the protein profiles of BBR-treated and control 3T3-L1 adipocytes --- p.85 / Chapter 4.7 --- Western blotting --- p.88 / Chapter 4.8 --- General discussion --- p.89 / Chapter 5. --- References --- p.92

Lors de l’obésité un état inflammatoire chronique de bas grade se développe dans le tissu adipeux et contribue à son dysfonctionnement participant ainsi au développement de l’insulino-résistance. Cette inflammation est due à une infiltration et une activation de différentes cellules immunitaires dans le tissu adipeux, dont des macrophages. Les acides gras saturés et le LPS participent à l’activation des cellules immunitaires conduisant ainsi à la production de cytokines inflammatoires, tous ces facteurs étant impliqués dans le dysfonctionnement du tissu adipeux et dans l’insulino-résistance. La kinase inflammatoire Tpl2 activée par le LPS et les cytokines, a récemment été identifiée comme une nouvelle kinase dont l’expression est augmentée dans le tissu d’obèses. Son rôle dans l’inflammation de ce tissu et dans la résistance à l’insuline est donc un axe de recherche majeur dans la recherche de nouvelles cibles thérapeutiques pour le traitement de l’obésité et des complications métaboliques qui lui sont associées. Nos résultats impliquent Tpl2 dans les effets délétères des macrophages activés par les acides gras ou le LPS sur la biologie des adipocytes. De même, l’inhibition pharmacologique de Tpl2 ou l’utilisation d’ARN interfèrent altère le potentiel chimiotactique du sécrétome d’adipocytes vis-à-vis des macrophages. Nos résultats indiquent que la kinase Tpl2 est activée par l’hypoxie dans les adipocytes et les macrophages, et que son inhibition entraîne une réduction de l’expression et de la production de facteurs inflammatoires. Ces études permettent de proposer Tpl2 comme cible thérapeutique potentielle dans le traitement de l’obésité et du diabète. / During obesity a chronic low grade inflammation is developed in adipose tissue and contributes to its malfunction and participating in the development of insulin resistance. This inflammation is due to the infiltration and activation of various immune cells in adipose tissue, such as macrophages. Saturated fatty acids and LPS are involved in immune cell activation and leading to the production of inflammatory cytokines, all of which are involved in the malfunction of adipose tissue and insulin resistance. The inflammatory TPL2 kinase activated by LPS and cytokines, has recently been identified as a novel kinase, whose expression is increased in obese tissue. Its role in the inflammation of this tissue and in the insulin resistance is a major area of research in the search for new therapeutic targets for the treatment of obesity and metabolic complications associated. Our results suggested that TPL2 is involved in the deleterious effects of macrophages activated by fatty acids or LPS on the biology of adipocytes. Similarly, the pharmacological inhibition of TPL2 or use of interfering RNA impairs chemotactic potential secretome of adipocytes versus the macrophages. Our results indicate that the TPL2 kinase is activated by hypoxia in adipocytes and macrophages, and its inhibition leads to a reduction of the expression and production of inflammatory factors. These studies suggested thatTPL2 is a potential therapeutic target in the treatment of obesity and diabetes.

Uncoupling protein, UCP, present in the inner mitochondrial membrane of brown adipose tissue (BAT) contributes to adaptive thermogenesis. UCP functions as a proton pore and can dissipate the proton electrochemical gradient established by the respiratory chain during fuel oxidation, and thus generates heat without producing ATP. However, the brown adipose tissue thermogenesis is not likely to be a major mechanism in controlling energy expenditure for humans because adults have only residual amounts of the tissue. Two new members of the UCP family have been identified based on their high sequence homology to UCP in BAT and named UCP2 and UCP3. The original UCP was renamed UCP1. At the amino acid level, human UCP2 and UCP3 are 59% and 57% identical to UCP1, respectively. In contrast to UCP1, UCP2 is expressed in many tissues such as brown adipose tissue, white adipose tissue, muscle, spleen and macrophages. UCP3 is expressed preferentially in skeletal muscle in humans, and brown adipose tissue and skeletal muscle in rodents. Since their identification many functional studies, including transgenic animals and ectopic expression of UCP2 or UCP3 in yeast, showed uncoupling activity of UCP2 and UCP3. A number of studies have been done that show increased expression of UCP2 and UCP3 by fasting, high-fat diets and suckling of newborn mice. A common characteristic of these circumstances is an associated increase in plasma free fatty acid levels. This study aimed to investigate effects of fatty acids, peroxisome proliferator-activated receptors (PPARs) and other transcription factors on UCP2 and UCP3 gene expression and to explore the molecular mechanism of their regulation through analysis of the promoter of the UCP2 and UCP3 genes. The 3.1 kb and 3.2 kb 5�-flanking regions of the mouse UCP2 and UCP3 genes, respectively, were cloned and used to construct promoter reporter gene (firefly luciferase) plasmids. The cloned region of the UCP2 and UCP3 genes contained putative binding motifs for several transcription factors, including PPAR, myogenin, and MyoD. Luciferase assays of both constructs showed basal promoter activity with 20~190-fold induction for the UCP2 promoter and 1.3~23-fold induction for the UCP3 promoter in several transfected cell lines, including 3T3-L1, C2C12, L6, COS7 and HepG2. Oleic acid (0.3 mM) up-regulated endogenous UCP2 mRNA by 2.3-fold in 3T3-L1 preadipocytes but not in C2C12 myotubes, and UCP3 mRNA by 2.5-fold in C2C12 myotubes. Responsiveness of the cloned promoter to oleic acid reflected the tissue-specific responsiveness of their endogenous genes but with less fold induction, 1.4-fold for UCP2 promoter in 3T3-L1 preadipocytes and 1.5-fold for UCP3 promoter in C2C12 myotubes. Forced expression of PPAR isotypes (PPARα, PPAR[delta] and PPARγ) showed tissue and isotype-specific activation of the UCP2 promoter. UCP2 promoter activity was induced by 2-fold by PPARγ in 3T3-L1 and by 2.8-fold by PPAR[delta] in C2C12. Treatment of oleic acid (0.3 mM) brought about further induction of the UCP2 promoter activity only in 3T3-L1. In contrast, all three isotypes induced activation of the UCP3 promoter in 3T3-L1, C2C12 and HepG2 cells. Treatment with oleic acid (0.3 mM) or isotype-specific agonist (10 [mu]M) resulted in further increased activity of the UCP3 promoter in 3T3-L1 and HepG2 cells. In particular, rosiglitazone (10 [mu]M) induced a 41-fold increase in UCP3 promoter activity in PPARγ transfected HepG2 cells, and this induction returned to basal level by treatment with bisphenol A diglycidyl ether (BADGE) (50 [mu]M), an antagonist for PPARγ. In addition, UCP3 promoter activity increased up to 20-fold 4 days after induction of C2C12 myoblasts differentiation, whereas UCP2 promoter activity increased only up to 2-fold. Forced expression of myogenin and MyoD in C2C12 myoblasts to mimic differentiation, induced UCP3 promoter activity in an additive manner, consistent with UCP3 being regulated by muscle differentiation. In the present study, it has been shown that UCP2 and UCP3 genes are regulated differently by fatty acids. The tissue-type dependence in regulation of endogenous UCP2 and UCP3 paralleled the cell type-specific effect of oleic acid on the promoter-reporter constructs, suggesting that fatty acid effects are at the transcriptional level. UCP2 and UCP3 promoters showed differences in their response to PPARs. Mediation of the fatty acid effect through PPARs has been also demonstrated, but direct binding of PPARs and particular regulatory motifs on the cloned promoter region have not yet been investigated.

Le tissu adipeux, outre son rôle de réserve énergétique, joue un rôle essentiel dans le contrôle de l'homéostasie du métabolisme ainsi que dans la physiopathologie de différentes affections, telles que diabète de type 2, dyslipidémies ou athérosclérose. Ce rôle est en partie assuré par des substances sécrétées par le tissu adipeux dans le plasma et regroupées sous le terme d'adipokines. Il s'agit notamment du tumor necrosis factor (TNF)-α, de la leptine, résistine ou encore de l'adiponectine (ApN). L'ApN se distingue des autres adipokines car, contrairement à l'augmentation des concentrations plasmatiques de leptine, de résistine ou de TNF-α observée dans l'obésité, ses taux sont corrélés de façon négative à l'indice de masse corporelle et de façon positive à la sensibilité à l'insuline. L'ApN joue donc un rôle très important dans la modulation du métabolisme lipidique et glucidique et/ou dans la régulation de l'insulinosensibilité. Afin d'étudier les répercussions in vivo d'une expression précoce et chronique d'ApN spécifiquement dans le tissu adipeux, nous avons créé des souris transgéniques où l'ADNc de l'ApN (forme complète) a été placé sous contrôle d'un promoteur adipocytaire. Selon le nombre de copies du transgène intégré dans le génome, nous obtenons des phénotypes forts différents, voire opposés. Dans notre étude réalisée chez des souris ayant intégré un nombre modeste de copies du transgène (6 copies), nous observons une diminution de l'expression (ARNm) et du contenu protéique en ApN du tissu adipeux. Ce rétrocontrôle négatif de la production d'ApN est associé à un phénotype d'intolérance au glucose et d'insulinorésistance, à une adiposité accrue probablement suite à la faible expression des molécules impliquées dans la dissipation d'énergie et à l'accroissement de la lipogenèse. Nous assistons également à une faible expression d'AdipoR2, l'isoforme du récepteur responsable de l'action de l'ApN sous sa forme complète. A l'inverse, les souris ayant intégré un grand nombre (100) de copies du transgène présentent une augmentation de l'expression et du contenu en ApN dans différents sites du tissu adipeux blanc (le phénomène de rétrocontrôle de l'ApN endogène étant masqué par une surexpression plus prononcée de l'ApN exogène). Cette surexpression d'ApN est associée à une amélioration attendue de l'homéostasie glucidique et du profil lipidique. De plus, ces souris présentent une nette réduction de leur adiposité secondaire à une augmentation de la dépense énergétique et, fait original, à une diminution de la différenciation adipocytaire. Le remaniement du tissu adipeux résulte en de petits adipocytes, caractérisés par une diminution d'expression des enzymes lipogéniques et de marqueurs adipocytaires, ainsi que par une augmentation d'expression de protéines découplantes et d'un marqueur préadipocytaire (Pref-1). Chez ces souris, l'expression d'AdipoR2 est accrue, peut-être suite à une réduction locale de TNFα. / Adipose tissue regulates fuel homeostasis and is implicated in the pathophysiology of several components of the metabolic syndrome, such as diabetes of type 2, dyslipidemia or atherosclerosis. The secretion of regulatory peptides, often referred to as adipocytokines, mediates in part these adipose functions. The best-known adipokines include tumor necrosis factor α (TNFα), leptin, resistin and adiponectin (ApN). Unlike the other adipokines, which are elevated in obesity, plasma ApN levels are negatively correlated to body mass index and positively to insulin sensitivity. Thus, ApN plays a fundamental role in regulating lipid and glucose metabolism, and insulin action. To study in vivo the chronic effects of ApN specifically on adipose tissue, we generated transgenic mouse lines allowing persistent and moderate expression of native full-length ApN targeted to white adipose tissue. We have obtained two different phenotypes according to the number of transgene copies integrated into the genome In our mouse lines with a modest copy number (6), we observed a decrease of expression (ARNm) and protein content of ApN in adipose tissue. This negative feedback on ApN production was associated with a phenotype of the glucose intolerance and insulin resistance, and with an increased adiposity due to low expression of molecules involved in energy expenditure, and to increased lipogenesis. We also observed a weak expression of AdipoR2, the receptor isoform responsible for the action of full-length ApN. On the contrary, mice with a high copy number (100), clearly overexpressed ApN in various sites of white fat (the downregulation of endogenous ApN being masked by the marked overexpression of exogenous ApN). This overexpression of ApN was associated with an expected improvement of glucose homeostasis and lipid profile. Furthermore, these mice showed reduced adiposity, due to increased energy expenditure and decreased adipocyte differentiation. Adipose tissue remodelling resulted in smaller (younger) adipocytes, characterized by a decrease of lipogenic enzymes and of adipocyte markers, as well as by an increased expression of uncoupling proteins and a preadipocyte marker (Pref-1). In this group of mice, the expression of AdipoR2 was enhanced possibly because of a local reduction of TNFα.

While diet and sedentary lifestyle remain important factors in the development of obesity, recent findings have shown the possible involvement of environmental obesogens, chemicals that can disrupt homeostatic energy balance and increase adiposity. Bisphenol A (BPA) is a compound used in the manufacturing of plastics as a hardening agent and is ubiquitous in the environment due to its widespread use. BPA has been shown to be an endocrine disruptor through its ability to mimic estrogen, which is now known to play important roles in adipose tissue growth and metabolism. In fact, a small but compelling number of studies have shown that mice exposed to BPA in utero or postnatally are fatter as adults. We hypothesized that BPA exposure exerts effects on adipose tissue, promoting adipogenesis and inflammation, and altering energy homeostasis in a manner that promotes obesity. We tested our hypothesis using both in vitro and in vivo models. First, we found that low concentrations of BPA increased the expression of the inflammatory genes, Il-6 and Tnfa, approximately 1.5-3.0 fold in mouse adipose tissue explants. We also found a 3-fold increase in the expression of the lipogenic gene, Fasn. BPA also altered the adipose tissue metabolism, increasing the levels of a number of glycolytic and TCA cycle metabolites, suggesting that BPA may disrupt energy homeostasis. We also found that BPA exposure increased proliferation of mesenchymal stem cells approximately 1.2-fold, which are potential adipocyteprecursors. The study was expanded using two different strains of mice, C57BL/6 and DBA/2J, chronically exposing them to BPA through drinking water for six weeks. A moderate concentration of BPA increased the perigonadal fat pad mass in males. This increase in adiposity was associated with adipocyte hypertrophy and decreased serum adiponectin levels. There were also changes in the expression of some genes with BPA treatment, including a 1.4-fold increase in Leptin and decreases in some Cytochrome P450 genes; however the genes differentially expressed were different between the two strains. Our results suggest that childhood exposure to low doses of BPA, in lieu of any developmental exposure, may contribute to childhood obesity.

A link between early malnutrition and development of components of the metabolic syndrome later in life has been shown in epidemiological and animal data. Moreover, studies now tend to demonstrate that not only fetal environment is important for developmental programming but postnatal milieu could also participate to this process. The “predictive adaptive response” hypothesis stipulates that not only a suboptimal environment during fetal life will lead to development of metabolic disorders later in life but more likely is a mismatch between the early environment and that one really encountered later on that increases the risk of developing later disease. Based on this hypothesis, we examined the effect of an early mismatched environment produced by fetal protein restriction and postnatal catch-up growth on the development of obesity and cardiovascular disease in male mice. We focussed our study on the analysis of adipose tissue with in vitro examination of differentiation, proliferation of preadipocytes. We also investigated in vivo the development of overweight in adult mice and we measured the expression of specific adipose tissue molecules with microarray. Finally, we investigated the development of hypertension and atherosclerosis in parallel to obesity. Our results indicated that postnatal catch-up growth after fetal protein restriction favours the development of obesiy in adult male mice. Early mismatched nutrition also influenced the capacity of proliferation of preadipocyte as well as the expression of adipose tissue specific molecules involved mainly in lipid biosynthesis. Finally, early nutrition also induced hypertension in adult male mice while no influence of fetal protein restriction and postnatal catch-up growth was observed on atherosclerosis development.